K
Klaus Krueger
Researcher at Praxis
Publications - 33
Citations - 882
Klaus Krueger is an academic researcher from Praxis. The author has contributed to research in topics: Rheumatoid arthritis & Internal medicine. The author has an hindex of 9, co-authored 28 publications receiving 776 citations.
Papers
More filters
Journal ArticleDOI
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Frank Behrens,Frank Behrens,Michaela Koehm,Michaela Koehm,T. Rossmanith,Rieke Alten,Martin Aringer,Marina Backhaus,Gerd R Burmester,Eugen Feist,Eva Herrmann,Herbert Kellner,Klaus Krueger,Annette Lehn,Ulf Müller-Ladner,Andrea Rubbert-Roth,Hans-Peter Tony,Siegfried Wassenberg,Harald Burkhardt,Harald Burkhardt +19 more
TL;DR: In this paper, the authors investigated the efficacy and safety of rituximab + LEF in patients with RA and found that the combination resulted in an increase in the ACR50 response rate that was significant at week 16 but not at week 24.
Journal ArticleDOI
No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis et al .
TL;DR: It is reassuring to note as interruption of clinically efficacious therapy in AIRD is associated with an increased risk of relapse which might lead to the necessity of intensifying immunosuppressive therapy, possibly beyond the original level.
Journal ArticleDOI
Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany.
TL;DR: Golimumab induces sustained improvements in WPAI and QoL and reduces healthcare resource utilization in RA, psoriatic arthritis and ankylosing spondylitis patients receiving golimumab under routine clinical settings in Germany.
Journal ArticleDOI
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci et al .
Hendrik Schulze-Koops,Klaus Krueger,Inka Vallbracht Vallbracht,Rebecca Hasseli,Alla Skapenko +4 more
TL;DR: Benucci et al. as mentioned in this paper showed that rituximab may inhibit the humoral response to SARS-CoV-2 and contribute to secondary worsening of COVID-19.
Proceedings ArticleDOI
SAT0187 Golimumab improves work productivity and activity impairment in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PSA): 1-year results from a non- interventional trial in germany
TL;DR: Golimumab leads to an improvement of work productivity and daily activities in all patients already within the first 3 months of treatment and provided sustained improvement in WPAI in patients with RA, PsA and AS.